Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4080 - IDO-1 and PD-L1 predict response to immunotherapy in advanced Non Small Cell Lung Cancer: an NGS and multiplex IHC analysis.


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Translational Research;  Non-Small Cell Lung Cancer


Laura Leroy


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


L. Leroy1, J. Massé2, J. Adam3, V. Brouste4, N. Signolle3, I. Soubeyran1, V. Velasco5, E. Khalifa1, B. Lortal6, A. Italiano7, B. Besse8, S. Le Moulec2

Author affiliations

  • 1 Département De Biopathologie, Institut BERGONIE, 33076 - Bordeaux/FR
  • 2 Pathology, Bergonié, 33 - Bordeaux/FR
  • 3 Pathology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Medical Oncology, Bergonié, 33 - Bordeaux/FR
  • 5 Pathology Department, Institute Bergonié, 33076 - Bordeaux/FR
  • 6 Pharmacological, Bergonié, 33 - Bordeaux/FR
  • 7 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 8 Oncologie Médical, Gustave Roussy, Villejuif/FR


Abstract 4080


PD1/PD-L1 inhibitors (IO) can be prescribed as first line treatment in high PD-L1 positive NSCLC pts. There is an important need for additional predictive factors to identify pts with PDL1 weak or negative NSCLC that could benefit from these.


In this retrospective study, pts with stage III/IV NSCLC eligible for an IO were selected. All pts consented for tissue analysis. Pt characteristics and outcome were collected. A NGS panel on 52 genes was performed with an immunochemistry analysis (PDL-1 with the SP-263 clone, CD8, PTEN, beta-catenine, MSI, FOXP3, IDO-1 and CD163). We used image analysis with density results. PD-L1 was classified as negative/weak/positive if 0/1-9%/10%+ of tumor cells were stained.


Sixty-seven pts were enrolled. Median age was 64 years, 8 pts were never smokers, 90% had PS 0-1, 11.3%/58.1%/30.6% received an IO as 1st/2nd/3rd line or more, 69% had a non-squamous carcinoma. 38.7% of the tumors were PD-L1 positive, and 15% weak. Median progression-free survival (PFS) was 3.5 months (IC95%, 1.9-7.6), 12 months overall survival rate was 63.3% (IC 95% 46.6-76.1). The objective response rate (ORR) was 50.8%. In univariate analysis PS, line of IO, positivity for PD-L1 (cut off 10%), CD8 (H-SCORE ≥ 284,4), FOXP3 (H-SCORE ≥ 155,4) and IDO-1 (H-SCORE ≥ 0,4) were significantly correlated with ORR and PFS. ORR was 77% in IDO-1 positive (n = 26), 32% in IDO-1 negative (n = 25) NSCLC pts. KRAS mutation, smoking status, histological type, response to platinum-based chemotherapy were not correlated with PFS and ORR. In multivariate analysis, positive PD-L1 and IDO-1 were the only factors correlated with ORR. ORR was 87.5% if both positive (n = 16), 60% if one of them was positive, 22.7% if both negative. Only IDO-1 was correlated with PFS.


Along with PD-L1, IDO-1 appears as a promising predictive factor for IO. A prospective validation is ongoing.

Clinical trial identification

Legal entity responsible for the study

Sylvestre Le Moulec




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.